- Home
- KRMD vs PBYI Comparison
KRMD vs PBYI Comparison
Compare KRMD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- PBYI
- Stock Information
- Founded
- KRMD 1980
- PBYI 2010
- Country
- KRMD United States
- PBYI United States
- Employees
- KRMD N/A
- PBYI N/A
- Industry
- KRMD Medical/Dental Instruments
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- KRMD Health Care
- PBYI Health Care
- Exchange
- KRMD Nasdaq
- PBYI Nasdaq
- Market Cap
- KRMD 127.0M
- PBYI 126.5M
- IPO Year
- KRMD N/A
- PBYI N/A
- Fundamental
- Price
- KRMD $2.64
- PBYI $2.65
- Analyst Decision
- KRMD Strong Buy
- PBYI Strong Buy
- Analyst Count
- KRMD 3
- PBYI 1
- Target Price
- KRMD $3.33
- PBYI $7.00
- AVG Volume (30 Days)
- KRMD 108.2K
- PBYI 293.8K
- Earning Date
- KRMD 11-06-2024
- PBYI 10-31-2024
- Dividend Yield
- KRMD N/A
- PBYI N/A
- EPS Growth
- KRMD N/A
- PBYI N/A
- EPS
- KRMD N/A
- PBYI 0.18
- Revenue
- KRMD $30,817,017.00
- PBYI $219,143,000.00
- Revenue This Year
- KRMD $15.46
- PBYI N/A
- Revenue Next Year
- KRMD $17.47
- PBYI N/A
- P/E Ratio
- KRMD N/A
- PBYI $14.61
- Revenue Growth
- KRMD 4.70
- PBYI N/A
- 52 Week Low
- KRMD $1.98
- PBYI $2.13
- 52 Week High
- KRMD $3.09
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- KRMD 54.05
- PBYI 52.38
- Support Level
- KRMD $2.46
- PBYI $2.41
- Resistance Level
- KRMD $2.74
- PBYI $2.69
- Average True Range (ATR)
- KRMD 0.16
- PBYI 0.14
- MACD
- KRMD -0.00
- PBYI 0.03
- Stochastic Oscillator
- KRMD 45.71
- PBYI 85.71
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.